Biliary atresia with aneurysmal dilatation of hepatic artery: A rare anomaly

Bindey Kumar1, Neelam Sinha, Prem Kumar

  • 1Department of Paediatric Surgery, Indira Gandhi Institute of Medical Sciences, Patna, India.

Insights

Biliary atresia rarely coexists with hepatic artery aneurysms. Recognizing this rare vascular anomaly is crucial for surgical planning and managing liver transplantation in affected children.

Area of Science:

  • Pediatric Surgery
  • Hepatology
  • Vascular Surgery

Background:

  • Biliary atresia is a serious neonatal liver disease.
  • Hepatic artery aneurysms are rare vascular malformations.
  • The coexistence of biliary atresia and hepatic artery aneurysm is exceptionally uncommon.

Purpose of the Study:

  • To highlight the rare association between biliary atresia and hepatic artery aneurysm.
  • To emphasize the importance of identifying this vascular anomaly in pediatric patients.
  • To discuss the implications for surgical management and liver transplantation.

Main Methods:

  • Case presentation of a four-month-old male infant with biliary atresia.
  • Intraoperative discovery of a cystic expansile mass.
  • Diagnostic confirmation of aneurysmal dilatation of the hepatic artery.

Main Results:

  • A four-month-old male presented with biliary atresia and an associated hepatic artery aneurysm.
  • The aneurysm was identified as a cystic expansile mass during surgical exploration.
  • This case confirms the rare co-occurrence of these two conditions.

Conclusions:

  • The association of hepatic artery aneurysm with biliary atresia is rare but significant.
  • Awareness of this anomaly aids in understanding biliary atresia's pathogenesis.
  • Identification is critical for planning liver transplantation and avoiding operative complications.
Abstract

Related Concept Videos

Routes of Drug Administration: Parenteral01:25

Routes of Drug Administration: Parenteral

The administration of drugs via parenteral routes allows for direct drug introduction into the systemic circulation, resulting in high bioavailability because the medication bypasses the harsh conditions of the gastrointestinal tract and hepatic metabolism.
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...
3.7K
Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
1.1K
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
2.1K
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
1.2K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K